October 27th, 2020
11 am to 12 pm EDT
Tremendous progress has been made for IBD patients starting with the approvals of anti-TNFs. In recent years, integrin blockers, JAK inhibitors, anti-12/23 and perhaps shortly S1P antagonist have all joined the list of IBD therapies.
However, the success in patients has highlighted the flaws in pre-clinical IBD models. None of the approved human treatments are efficacious in all rodent IBD models. In fact, many successful human treatments work only in one of
the many rodent IBD models. In this webinar we will review the utility of the rodent and NHP models of IBD and the predictive value with specific focus on choosing the correct IBD model to avoid false negative results because of incorrect
pre-clinical model choice.
Jeffery Cowden, PhD
Executive Director of Pharmacology
Jeffery is an experienced drug hunter with over 18 years of working experience at large pharmaceutical companies focusing on autoimmunity, allergy and cancer. He has published on the effects of novel drugs in RA, asthma and atopic dermatitis.
His work has contributed to 8 IND filings over his career.
Cost: No Cost!